Method for the production of sub-micrometric particles and their theranostic use in oncology with a specific apparatus

{
  "publication_number": "US2016008467A1",
  "country": "US",
  "kind": "A1",
  "title": "Method for the production of sub-micrometric particles and their theranostic use in oncology with a specific apparatus",
  "abstract": "The invention relates to a method for producing sub-micrometric particles, which comprises: mechanochemical treatment of homogeneous or heterogeneous magnetic materials until a mass which consists mostly of magnetic nanocrystal aggregates is obtained; selection of aggregates so that the nanocrystals have a Curie temperature within a predefined variation range; functionalization of the aggregates in order to obtain coating thereof with molecules of one or more of the following types of substances: substances for which the tumour cells have a particular metabolic avidity; substances having a biochemical affinity with the tumour cells; substances having an affinity with the acid microenvironment which surrounds the neoplastic cells. In addition to the method the following are claimed: the particles thus produced; their theranostic use which allows the in vivo execution, without interruption, of the diagnosis or monitoring step and the therapy step by means of magnetic hyperthermia of malignant neoplasms, including those localized in the so-called “sanctuary sites” such as the central nervous system and the testicle; an apparatus designed for this use.",
  "claims": [
    "1. Method for the production of sub-micrometric particles for the in vivo treatment of tumour cells, comprising the steps of: A. mechanochemical treatment of homogeneous or heterogeneous, powdery, magnetic materials in a controlled atmosphere, and in the presence of a liquid phase of not more than 5% by volume, until a consistent mass with at least 80% by volume of magnetic aggregates mainly with dimensions smaller than 500 nm is obtained, said aggregates being formed by magnetic nanocrystals mainly with dimensions smaller than 100 nm; B. dispersion of the magnetic aggregates in a fluid; C. dimensional selection and distribution of the magnetic aggregates present in the said fluid depending on their Curie temperature within a predefined variation range (T min -T max); D. functionalization by coating the aggregates with substances designed to generate a mutual attraction between the tumour cells and the nanocrystals of the magnetic aggregates. 2. Method according to claim 1, wherein the mechanochemical treatment takes place, in a high-energy mill or, alternatively, in a mechanochemical reactor, where an atmosphere with a controlled oxygen content is maintained. 3. Method according to claim 1 or claim 2, wherein the dimensional selection and distribution of the magnetic nanocrystal aggregates dispersed in a biocompatible fluid comprises in succession: a) heating and keeping the fluid at the maximum temperature of the predefined variation range T max; b) removing from the fluid by means of a first magnetic filter the aggregates having a Curie temperature greater than T max c) cooling the fluid from which the said aggregates have been removed to the minimum temperature within the predefined variation range T min and keeping the fluid at said temperature; d) removing from the fluid by means of a second magnetic filter the aggregates having a Curie temperature within the range T min -T max with a view to subsequent oncological use. 4. Method according to any one of claims 1 to 3, wherein functionalization of the aggregates is performed using molecules of substances for which the tumour cells have a particular metabolic avidity, such as monosaccharide carbohydrates, in particular glucose. 5. Method according to any one of claims 1 to 3, wherein the functionalization of the aggregates is performed using molecules of substances having a biochemical affinity with the tumour cells such as monoclonal antibodies. 6. Method according to any one of claims 1 to 3, wherein functionalization of the aggregates is performed using molecules of substances having an affinity with the acid microenvironment which surrounds the tumour cells such as linear polysaccharides, in particular chitosan. 7. Sub-micrometric particles for theranostic use in the treatment of neoplasms, obtained according to the methods of any one of the preceding claims, comprising: an aggregate of nanocrystals of at least one of the following magnetic materials: iron oxides, also of a mixed and complex nature; intermetallic compounds and iron-containing magnetic alloys; magnetic systems consisting of iron with other metals. a coating of the said aggregate of magnetic nanocrystals comprising molecules of at least one of the following types of substances: substances for which the tumour cells have a particular metabolic avidity; substances having a biochemical affinity with the tumour cells; substances having an affinity with the acid microenvironment which surrounds the neoplastic cells. 8. Theranostic use in oncology of sub-micrometric particles produced with the method according to any one of claims 1 to 6 and/or claim 7, comprising in succession and without interruption the steps of: A. introducing intravenously the sub-micrometric particles into the patient's body using a compatible physiological solution; B. diagnosis and/or monitoring of tumour cells by means of location of the magnetic nanocrystal aggregates concentrated in the vicinity or inside the said cells as a result of attraction of the molecules of the coating of the magnetic nanocrystal aggregates by means of a magnetic resonance imaging system known per se; C. localized heating, inductively, of the magnetic nanocrystals to a temperature within a predefined variation range of the Curie temperature having, as an effect, the destruction of the tumour cells by means magnetic hyperthermia; D. detection of the loss of the magnetic properties of the nanocrystals upon reaching the Curie temperature by means of the said imaging system known per se; and E. simultaneous stoppage of said heating operation so as to ensure that the healthy tissue surrounding the tumour cells remains undamaged, since it is at a lower temperature. 9. Apparatus for implementing a theranostic use in oncology according to claim 8, the apparatus being based on a magnetic resonance imaging (MRI) system known per se and also comprising means for generating an electromagnetic field designed to heat inductively, to a value within a predefined variation range of the Curie temperature, the magnetic nanocrystal aggregates forming part of the sub-micrometric particles previously introduced intravenously into the patient's body. 10. Apparatus for implementing a theranostic use in oncology according to claim 9, characterized in that said heating means are designed to stop following the loss of the magnetic properties of the nanoparticles. 11. Apparatus according to either one of claims 9 to 10, wherein the means for generating a variable electromagnetic field comprise one or more induction coils and means for varying the parameters of the said field and directing it towards the zone of the patient's body where a neoplasm is assumed to be present."
  ],
  "cpc": [
    "A61K 41/0052",
    "A61B 5/055",
    "A61K 49/1824",
    "A61K 49/1863",
    "A61K 9/5123",
    "A61K 9/5192",
    "A61M 5/007",
    "A61N 1/403",
    "A61N 1/406",
    "A61N 2/004",
    "A61N 2/02",
    "A61P 35/00",
    "G01R 33/281"
  ],
  "assignees": [
    "MBN NANOMATERIALIA SPA"
  ],
  "filing_date": "2014-02-28",
  "publication_date": "2016-01-14",
  "priority_date": "2013-02-28",
  "application_number": "US-201414770553-A",
  "family_id": "48184398",
  "citations": [
    "US2006246143A1",
    "US4690130A",
    "US5492814A"
  ]
}